Understanding drug resistance in tuberculosis treatment for HIV patients
Emergence of bedaquiline and clofazimine resistance after interruption of drug-resistant TB therapy in a high HIV prevalence setting
This study looks at how stopping TB treatment affects drug resistance, especially in people also living with HIV, and it explores whether new medications can help improve treatment outcomes and reduce resistance, aiming to find better ways to treat drug-resistant TB in areas where HIV is common.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-10975904 on NIH RePORTER |
What this research studies
This research investigates the emergence of drug resistance in tuberculosis (TB) among patients who have interrupted their treatment, particularly focusing on those co-infected with HIV. It examines how the use of new medications like bedaquiline and clofazimine can impact treatment outcomes and resistance patterns. By analyzing patient data and treatment regimens, the study aims to identify risks associated with treatment interruptions and develop strategies to mitigate resistance. The findings could lead to improved treatment protocols for drug-resistant TB in high HIV prevalence settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with drug-resistant tuberculosis who are also living with HIV.
Not a fit: Patients who do not have drug-resistant tuberculosis or are not co-infected with HIV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for drug-resistant TB, ultimately improving survival rates for patients co-infected with HIV.
How similar studies have performed: Previous research has shown promising results in managing drug-resistant TB with new medications, indicating that this approach has potential for success.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Brust, James C M — Albert Einstein College of Medicine
- Study coordinator: Brust, James C M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.